| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drosophila melanogaster | 36 | 2020 | 80 | 9.070 |
Why?
|
| Aging | 32 | 2020 | 911 | 5.890 |
Why?
|
| Biological Evolution | 24 | 2019 | 86 | 5.360 |
Why?
|
| Longevity | 27 | 2020 | 60 | 4.900 |
Why?
|
| Selection, Genetic | 28 | 2019 | 49 | 4.020 |
Why?
|
| Muscular Diseases | 11 | 2018 | 41 | 3.440 |
Why?
|
| Genomics | 9 | 2019 | 168 | 2.800 |
Why?
|
| Models, Biological | 18 | 2020 | 981 | 2.630 |
Why?
|
| Drosophila | 15 | 2019 | 37 | 2.560 |
Why?
|
| Adaptation, Physiological | 14 | 2020 | 189 | 2.100 |
Why?
|
| Evolution, Molecular | 11 | 2019 | 79 | 1.720 |
Why?
|
| Quality of Life | 12 | 2020 | 1515 | 1.690 |
Why?
|
| Environment | 7 | 2020 | 115 | 1.430 |
Why?
|
| Animals | 63 | 2020 | 20881 | 1.310 |
Why?
|
| Models, Genetic | 8 | 2018 | 161 | 1.240 |
Why?
|
| Fertility | 18 | 2020 | 60 | 1.150 |
Why?
|
| Reproduction | 6 | 2016 | 48 | 1.150 |
Why?
|
| Exercise | 2 | 2021 | 658 | 1.040 |
Why?
|
| Genetic Techniques | 2 | 2018 | 32 | 1.010 |
Why?
|
| Mortality | 7 | 2009 | 163 | 1.000 |
Why?
|
| Phenotype | 10 | 2019 | 947 | 1.000 |
Why?
|
| Accelerometry | 2 | 2021 | 61 | 0.970 |
Why?
|
| Caloric Restriction | 5 | 2008 | 22 | 0.860 |
Why?
|
| Affect | 3 | 2013 | 218 | 0.810 |
Why?
|
| Fitness Trackers | 1 | 2021 | 5 | 0.800 |
Why?
|
| Models, Animal | 5 | 2010 | 252 | 0.780 |
Why?
|
| Models, Statistical | 6 | 2016 | 448 | 0.760 |
Why?
|
| Adaptation, Biological | 6 | 2019 | 14 | 0.750 |
Why?
|
| Frailty | 1 | 2021 | 34 | 0.730 |
Why?
|
| Motor Activity | 2 | 2014 | 621 | 0.720 |
Why?
|
| Humans | 60 | 2021 | 68618 | 0.700 |
Why?
|
| Patient Safety | 2 | 2018 | 202 | 0.670 |
Why?
|
| Mastectomy, Segmental | 1 | 2019 | 64 | 0.660 |
Why?
|
| Mastectomy | 1 | 2019 | 57 | 0.660 |
Why?
|
| Age Factors | 8 | 2014 | 1864 | 0.650 |
Why?
|
| Acceptance and Commitment Therapy | 1 | 2018 | 4 | 0.650 |
Why?
|
| Betacoronavirus | 1 | 2020 | 116 | 0.640 |
Why?
|
| Surveys and Questionnaires | 12 | 2021 | 2800 | 0.640 |
Why?
|
| Genetic Variation | 7 | 2018 | 220 | 0.610 |
Why?
|
| Water Purification | 1 | 2019 | 168 | 0.590 |
Why?
|
| Medical Errors | 1 | 2018 | 80 | 0.590 |
Why?
|
| Checklist | 1 | 2018 | 76 | 0.580 |
Why?
|
| Flight, Animal | 1 | 2017 | 1 | 0.580 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 143 | 0.580 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2017 | 20 | 0.580 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 154 | 0.580 |
Why?
|
| Operating Rooms | 1 | 2018 | 108 | 0.570 |
Why?
|
| Chronic Pain | 1 | 2018 | 110 | 0.570 |
Why?
|
| Female | 45 | 2020 | 38074 | 0.570 |
Why?
|
| Stress, Physiological | 2 | 2009 | 215 | 0.560 |
Why?
|
| Life History Traits | 1 | 2016 | 1 | 0.560 |
Why?
|
| Systems Biology | 2 | 2014 | 25 | 0.560 |
Why?
|
| Directed Molecular Evolution | 3 | 2011 | 6 | 0.550 |
Why?
|
| Personal Satisfaction | 1 | 2017 | 123 | 0.530 |
Why?
|
| Reproducibility of Results | 10 | 2021 | 2077 | 0.530 |
Why?
|
| Death | 1 | 2016 | 38 | 0.520 |
Why?
|
| Students, Medical | 1 | 2018 | 210 | 0.520 |
Why?
|
| Adult | 25 | 2021 | 21403 | 0.510 |
Why?
|
| Diet Therapy | 1 | 2015 | 22 | 0.510 |
Why?
|
| Water Pollutants, Chemical | 1 | 2019 | 328 | 0.510 |
Why?
|
| Communicable Disease Control | 1 | 2015 | 26 | 0.500 |
Why?
|
| Communicable Diseases | 1 | 2015 | 50 | 0.490 |
Why?
|
| Drosophila Proteins | 2 | 2019 | 44 | 0.490 |
Why?
|
| Genetics, Population | 6 | 2019 | 21 | 0.490 |
Why?
|
| Psychotherapy | 1 | 2017 | 253 | 0.480 |
Why?
|
| Mood Disorders | 2 | 2015 | 132 | 0.480 |
Why?
|
| Gene Frequency | 6 | 2018 | 207 | 0.480 |
Why?
|
| Consumer Behavior | 1 | 2014 | 68 | 0.470 |
Why?
|
| Male | 39 | 2020 | 37321 | 0.470 |
Why?
|
| Algorithms | 3 | 2018 | 1196 | 0.460 |
Why?
|
| Sickness Impact Profile | 1 | 2013 | 27 | 0.460 |
Why?
|
| Phylogeny | 6 | 2009 | 197 | 0.450 |
Why?
|
| Computer Simulation | 5 | 2018 | 706 | 0.440 |
Why?
|
| Genome, Insect | 4 | 2018 | 7 | 0.430 |
Why?
|
| Severity of Illness Index | 5 | 2015 | 1851 | 0.420 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 1293 | 0.420 |
Why?
|
| Population Dynamics | 3 | 2013 | 30 | 0.410 |
Why?
|
| Animals, Laboratory | 5 | 2013 | 21 | 0.390 |
Why?
|
| Quality of Health Care | 1 | 2014 | 322 | 0.390 |
Why?
|
| Muscles | 2 | 2021 | 158 | 0.390 |
Why?
|
| Perception | 1 | 2012 | 189 | 0.380 |
Why?
|
| Mutation | 7 | 2016 | 1213 | 0.380 |
Why?
|
| Delivery of Health Care | 2 | 2018 | 445 | 0.380 |
Why?
|
| Depression | 1 | 2018 | 943 | 0.370 |
Why?
|
| Charcot-Marie-Tooth Disease | 2 | 2012 | 4 | 0.370 |
Why?
|
| Starvation | 5 | 2019 | 8 | 0.370 |
Why?
|
| Psychometrics | 6 | 2020 | 514 | 0.370 |
Why?
|
| Diet | 3 | 2020 | 514 | 0.360 |
Why?
|
| Muscular Dystrophy, Facioscapulohumeral | 1 | 2010 | 1 | 0.360 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 447 | 0.360 |
Why?
|
| Disability Evaluation | 3 | 2014 | 298 | 0.350 |
Why?
|
| Scapula | 1 | 2010 | 36 | 0.350 |
Why?
|
| Aged | 13 | 2021 | 14862 | 0.340 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 1536 | 0.340 |
Why?
|
| Body Contouring | 2 | 2020 | 2 | 0.340 |
Why?
|
| Research Design | 4 | 2014 | 729 | 0.340 |
Why?
|
| Heterozygote | 5 | 2018 | 174 | 0.330 |
Why?
|
| Hypnotics and Sedatives | 1 | 2009 | 96 | 0.320 |
Why?
|
| Neuromuscular Diseases | 3 | 2014 | 14 | 0.320 |
Why?
|
| Biology | 1 | 2007 | 14 | 0.300 |
Why?
|
| Survival Rate | 4 | 2019 | 1056 | 0.300 |
Why?
|
| Molecular Biology | 1 | 2007 | 31 | 0.300 |
Why?
|
| Regression Analysis | 4 | 2013 | 737 | 0.300 |
Why?
|
| Geriatrics | 1 | 2008 | 69 | 0.300 |
Why?
|
| United Kingdom | 3 | 2018 | 152 | 0.290 |
Why?
|
| Veterans | 2 | 2006 | 904 | 0.290 |
Why?
|
| Young Adult | 8 | 2019 | 5717 | 0.290 |
Why?
|
| Central Nervous System Stimulants | 1 | 2009 | 221 | 0.290 |
Why?
|
| Technology, Pharmaceutical | 1 | 2006 | 8 | 0.280 |
Why?
|
| Social Adjustment | 1 | 2007 | 74 | 0.280 |
Why?
|
| Genetic Heterogeneity | 1 | 2006 | 11 | 0.280 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 4848 | 0.280 |
Why?
|
| Gulf War | 1 | 2006 | 22 | 0.270 |
Why?
|
| Computational Biology | 1 | 2007 | 190 | 0.270 |
Why?
|
| Middle Aged | 15 | 2019 | 21147 | 0.270 |
Why?
|
| Pharmacology, Clinical | 1 | 2006 | 13 | 0.260 |
Why?
|
| Feasibility Studies | 2 | 2021 | 652 | 0.260 |
Why?
|
| Physiology | 1 | 2005 | 12 | 0.260 |
Why?
|
| Peripheral Nerves | 1 | 2005 | 22 | 0.260 |
Why?
|
| Eating | 1 | 2006 | 119 | 0.260 |
Why?
|
| Alleles | 3 | 2016 | 386 | 0.260 |
Why?
|
| Health Status | 2 | 2012 | 429 | 0.260 |
Why?
|
| Patient Satisfaction | 4 | 2020 | 378 | 0.250 |
Why?
|
| Nervous System Diseases | 1 | 2006 | 142 | 0.250 |
Why?
|
| Research | 1 | 2006 | 214 | 0.240 |
Why?
|
| Biomedical Research | 1 | 2008 | 310 | 0.240 |
Why?
|
| Wounds and Injuries | 1 | 2007 | 334 | 0.230 |
Why?
|
| Myositis, Inclusion Body | 3 | 2016 | 5 | 0.230 |
Why?
|
| Time Factors | 7 | 2014 | 4655 | 0.230 |
Why?
|
| Persian Gulf Syndrome | 1 | 2003 | 27 | 0.230 |
Why?
|
| Prognosis | 3 | 2019 | 2093 | 0.230 |
Why?
|
| Neurologic Examination | 2 | 2014 | 107 | 0.230 |
Why?
|
| Water | 2 | 2019 | 230 | 0.220 |
Why?
|
| Warfare | 1 | 2003 | 58 | 0.220 |
Why?
|
| Polymorphism, Genetic | 2 | 2014 | 301 | 0.210 |
Why?
|
| Activities of Daily Living | 3 | 2014 | 319 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 3 | 2016 | 772 | 0.210 |
Why?
|
| Immunologic Factors | 2 | 2016 | 87 | 0.210 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 498 | 0.210 |
Why?
|
| Clinical Trials as Topic | 4 | 2016 | 848 | 0.210 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2003 | 99 | 0.200 |
Why?
|
| Tibial Nerve | 2 | 2012 | 10 | 0.200 |
Why?
|
| Nerve Compression Syndromes | 2 | 2012 | 16 | 0.200 |
Why?
|
| Diabetic Neuropathies | 2 | 2012 | 33 | 0.200 |
Why?
|
| Health Status Indicators | 2 | 2013 | 117 | 0.200 |
Why?
|
| Heart | 2 | 2017 | 850 | 0.200 |
Why?
|
| Body Weight | 2 | 2019 | 554 | 0.200 |
Why?
|
| Genetics | 2 | 2014 | 6 | 0.200 |
Why?
|
| Genome | 3 | 2011 | 54 | 0.200 |
Why?
|
| Bariatric Surgery | 2 | 2020 | 90 | 0.200 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2018 | 627 | 0.190 |
Why?
|
| Orthopedic Procedures | 2 | 2015 | 102 | 0.190 |
Why?
|
| Los Angeles | 1 | 2021 | 30 | 0.190 |
Why?
|
| Locomotion | 2 | 2017 | 135 | 0.190 |
Why?
|
| Monitoring, Ambulatory | 1 | 2021 | 84 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2018 | 931 | 0.190 |
Why?
|
| Adolescent | 7 | 2017 | 8912 | 0.190 |
Why?
|
| Independent Living | 1 | 2021 | 44 | 0.180 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 219 | 0.180 |
Why?
|
| Muscle, Skeletal | 3 | 2014 | 396 | 0.170 |
Why?
|
| Acetanilides | 1 | 2019 | 9 | 0.170 |
Why?
|
| Halogenation | 1 | 2019 | 35 | 0.170 |
Why?
|
| Attitude to Health | 2 | 2012 | 403 | 0.170 |
Why?
|
| Desiccation | 3 | 2018 | 11 | 0.170 |
Why?
|
| Species Specificity | 3 | 2019 | 303 | 0.170 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 57 | 0.170 |
Why?
|
| Genotype | 3 | 2014 | 786 | 0.170 |
Why?
|
| Depressive Disorder | 2 | 2018 | 621 | 0.160 |
Why?
|
| Linear Models | 1 | 2020 | 521 | 0.160 |
Why?
|
| Striae Distensae | 1 | 2018 | 1 | 0.160 |
Why?
|
| Selective Breeding | 1 | 2018 | 1 | 0.160 |
Why?
|
| Receptors, Estrogen | 1 | 2019 | 142 | 0.160 |
Why?
|
| Hospitals | 1 | 2021 | 265 | 0.160 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 186 | 0.160 |
Why?
|
| Receptor, ErbB-2 | 1 | 2019 | 129 | 0.160 |
Why?
|
| Disinfection | 1 | 2019 | 112 | 0.160 |
Why?
|
| Civil Rights | 1 | 2018 | 10 | 0.160 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 42 | 0.160 |
Why?
|
| Genetic Linkage | 1 | 2018 | 90 | 0.160 |
Why?
|
| Formative Feedback | 1 | 2018 | 8 | 0.160 |
Why?
|
| Sample Size | 1 | 2018 | 79 | 0.160 |
Why?
|
| Genetic Drift | 3 | 2013 | 4 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 186 | 0.150 |
Why?
|
| Delphi Technique | 2 | 2016 | 62 | 0.150 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 2 | 2010 | 56 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 369 | 0.150 |
Why?
|
| Transcriptome | 1 | 2019 | 164 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 2 | 2013 | 329 | 0.150 |
Why?
|
| Social Stigma | 1 | 2018 | 53 | 0.150 |
Why?
|
| Karyotyping | 1 | 2017 | 74 | 0.150 |
Why?
|
| Online Systems | 1 | 2017 | 20 | 0.140 |
Why?
|
| History, 20th Century | 2 | 2008 | 248 | 0.140 |
Why?
|
| Domestication | 1 | 2016 | 1 | 0.140 |
Why?
|
| Food Deprivation | 1 | 2017 | 22 | 0.140 |
Why?
|
| Disabled Persons | 1 | 2018 | 94 | 0.140 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 124 | 0.140 |
Why?
|
| United States | 4 | 2018 | 7367 | 0.140 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 177 | 0.140 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2016 | 22 | 0.140 |
Why?
|
| Pandemics | 1 | 2020 | 352 | 0.140 |
Why?
|
| Markov Chains | 1 | 2016 | 133 | 0.140 |
Why?
|
| Models, Psychological | 1 | 2017 | 180 | 0.130 |
Why?
|
| Patient Care Team | 1 | 2018 | 311 | 0.130 |
Why?
|
| Surgical Fixation Devices | 1 | 2015 | 1 | 0.130 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2016 | 52 | 0.130 |
Why?
|
| Genetic Speciation | 2 | 2013 | 4 | 0.130 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2016 | 138 | 0.130 |
Why?
|
| Hemothorax | 1 | 2015 | 9 | 0.130 |
Why?
|
| Sternum | 1 | 2015 | 19 | 0.130 |
Why?
|
| Obesity | 2 | 2020 | 1076 | 0.130 |
Why?
|
| Bone Plates | 1 | 2015 | 49 | 0.130 |
Why?
|
| Crosses, Genetic | 2 | 2004 | 60 | 0.120 |
Why?
|
| Caenorhabditis elegans | 2 | 2006 | 38 | 0.120 |
Why?
|
| Health Care Reform | 1 | 2014 | 62 | 0.120 |
Why?
|
| Endpoint Determination | 1 | 2014 | 82 | 0.120 |
Why?
|
| Animals, Outbred Strains | 1 | 2013 | 4 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2018 | 413 | 0.120 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 174 | 0.110 |
Why?
|
| Postal Service | 1 | 2013 | 19 | 0.110 |
Why?
|
| Genome-Wide Association Study | 2 | 2014 | 240 | 0.110 |
Why?
|
| International Classification of Diseases | 1 | 2014 | 85 | 0.110 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2013 | 4 | 0.110 |
Why?
|
| Cross-Cultural Comparison | 1 | 2014 | 68 | 0.110 |
Why?
|
| Child | 7 | 2016 | 6405 | 0.110 |
Why?
|
| Polymyositis | 1 | 2013 | 5 | 0.110 |
Why?
|
| Dermatomyositis | 1 | 2013 | 31 | 0.110 |
Why?
|
| Deuterium | 1 | 2013 | 10 | 0.110 |
Why?
|
| Forecasting | 1 | 2014 | 277 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1553 | 0.110 |
Why?
|
| Illness Behavior | 1 | 2012 | 4 | 0.110 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2012 | 13 | 0.110 |
Why?
|
| Chronic Disease | 4 | 2016 | 1330 | 0.110 |
Why?
|
| Gait | 1 | 2014 | 120 | 0.110 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 3259 | 0.100 |
Why?
|
| Posterior Horn Cells | 1 | 2012 | 4 | 0.100 |
Why?
|
| Cell Differentiation | 1 | 2016 | 1034 | 0.100 |
Why?
|
| Portugal | 2 | 2019 | 7 | 0.100 |
Why?
|
| Child, Preschool | 4 | 2016 | 3187 | 0.100 |
Why?
|
| Deglutition Disorders | 1 | 2016 | 297 | 0.100 |
Why?
|
| Pain Perception | 1 | 2012 | 22 | 0.100 |
Why?
|
| DNA, Mitochondrial | 1 | 2012 | 84 | 0.100 |
Why?
|
| Immunity, Innate | 2 | 2003 | 156 | 0.100 |
Why?
|
| Motion | 1 | 2012 | 24 | 0.100 |
Why?
|
| Analysis of Variance | 4 | 2013 | 1040 | 0.100 |
Why?
|
| Diabetic Foot | 1 | 2012 | 33 | 0.100 |
Why?
|
| Decompression, Surgical | 1 | 2012 | 55 | 0.100 |
Why?
|
| Foot | 1 | 2012 | 66 | 0.100 |
Why?
|
| Likelihood Functions | 1 | 2012 | 106 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 629 | 0.100 |
Why?
|
| Quantitative Trait Loci | 1 | 2011 | 35 | 0.100 |
Why?
|
| Sexual Behavior, Animal | 2 | 2007 | 13 | 0.090 |
Why?
|
| Emotions | 1 | 2012 | 244 | 0.090 |
Why?
|
| Myositis | 2 | 2016 | 24 | 0.090 |
Why?
|
| Incidence | 2 | 2006 | 1603 | 0.090 |
Why?
|
| Qualitative Research | 3 | 2018 | 369 | 0.090 |
Why?
|
| Infant | 3 | 2016 | 2891 | 0.090 |
Why?
|
| Lambert-Eaton Myasthenic Syndrome | 1 | 2010 | 1 | 0.090 |
Why?
|
| Myasthenia Gravis | 1 | 2010 | 17 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 33 | 0.090 |
Why?
|
| Attention | 1 | 2012 | 225 | 0.090 |
Why?
|
| Muscular Dystrophies | 1 | 2010 | 17 | 0.090 |
Why?
|
| Behavior, Animal | 1 | 2012 | 470 | 0.080 |
Why?
|
| History, 19th Century | 1 | 2008 | 95 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2008 | 127 | 0.080 |
Why?
|
| Helminths | 1 | 2008 | 2 | 0.080 |
Why?
|
| Artifacts | 1 | 2009 | 125 | 0.080 |
Why?
|
| Sirtuins | 1 | 2008 | 16 | 0.080 |
Why?
|
| Founder Effect | 3 | 2014 | 5 | 0.080 |
Why?
|
| Rhodiola | 1 | 2007 | 1 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2016 | 2455 | 0.080 |
Why?
|
| Hemolymph | 1 | 2007 | 3 | 0.080 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2007 | 15 | 0.080 |
Why?
|
| Hybrid Vigor | 1 | 2007 | 1 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2015 | 1615 | 0.070 |
Why?
|
| Myopathies, Structural, Congenital | 1 | 2007 | 2 | 0.070 |
Why?
|
| Glycogen | 1 | 2007 | 27 | 0.070 |
Why?
|
| Thiazolidinediones | 1 | 2007 | 77 | 0.070 |
Why?
|
| Stochastic Processes | 1 | 2006 | 27 | 0.070 |
Why?
|
| Heredity | 1 | 2006 | 9 | 0.070 |
Why?
|
| Hospitalization | 1 | 2012 | 978 | 0.070 |
Why?
|
| Nervous System | 1 | 2006 | 45 | 0.070 |
Why?
|
| Pharmaceutical Preparations | 1 | 2006 | 101 | 0.060 |
Why?
|
| Oviposition | 1 | 2005 | 30 | 0.060 |
Why?
|
| Proteomics | 1 | 2007 | 246 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 1745 | 0.060 |
Why?
|
| Lipids | 1 | 2007 | 298 | 0.060 |
Why?
|
| Europe | 2 | 2017 | 196 | 0.060 |
Why?
|
| Guidelines as Topic | 1 | 2006 | 123 | 0.060 |
Why?
|
| Nerve Growth Factors | 1 | 2005 | 75 | 0.060 |
Why?
|
| Life Cycle Stages | 1 | 2004 | 7 | 0.060 |
Why?
|
| Energy Intake | 1 | 2005 | 123 | 0.060 |
Why?
|
| Hypoglycemic Agents | 1 | 2007 | 362 | 0.060 |
Why?
|
| Population Density | 3 | 2009 | 18 | 0.060 |
Why?
|
| Energy Metabolism | 1 | 2006 | 222 | 0.060 |
Why?
|
| Epidemiologic Methods | 1 | 2004 | 83 | 0.060 |
Why?
|
| Nutritional Status | 1 | 2005 | 112 | 0.060 |
Why?
|
| Age of Onset | 1 | 2003 | 188 | 0.050 |
Why?
|
| Time | 1 | 2003 | 57 | 0.050 |
Why?
|
| Epilepsy | 1 | 2007 | 336 | 0.050 |
Why?
|
| Oxygen Consumption | 1 | 2004 | 258 | 0.050 |
Why?
|
| Age Distribution | 1 | 2003 | 320 | 0.050 |
Why?
|
| Genetic Fitness | 2 | 2014 | 8 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2004 | 224 | 0.050 |
Why?
|
| Demography | 1 | 2003 | 279 | 0.050 |
Why?
|
| Disease Progression | 1 | 2005 | 1038 | 0.050 |
Why?
|
| Models, Theoretical | 2 | 2019 | 384 | 0.050 |
Why?
|
| Sex Factors | 1 | 2005 | 1266 | 0.050 |
Why?
|
| Prevalence | 1 | 2006 | 1619 | 0.050 |
Why?
|
| Geography | 2 | 2014 | 80 | 0.050 |
Why?
|
| Haplotypes | 2 | 2014 | 174 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2003 | 269 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2003 | 295 | 0.050 |
Why?
|
| Netherlands | 2 | 2015 | 68 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2013 | 7277 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2002 | 328 | 0.040 |
Why?
|
| Denmark | 1 | 2020 | 24 | 0.040 |
Why?
|
| International Cooperation | 2 | 2014 | 88 | 0.040 |
Why?
|
| Photoperiod | 1 | 2019 | 11 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2014 | 7029 | 0.040 |
Why?
|
| Beauveria | 1 | 2018 | 1 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 114 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 2550 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2020 | 332 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2003 | 2358 | 0.040 |
Why?
|
| Karyotype | 1 | 2017 | 7 | 0.040 |
Why?
|
| Safety Management | 1 | 2018 | 73 | 0.040 |
Why?
|
| Body Size | 1 | 2017 | 39 | 0.040 |
Why?
|
| Program Development | 1 | 2018 | 240 | 0.030 |
Why?
|
| Health Services Research | 1 | 2018 | 209 | 0.030 |
Why?
|
| Leadership | 1 | 2018 | 136 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2018 | 188 | 0.030 |
Why?
|
| Weight Loss | 1 | 2018 | 319 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2018 | 502 | 0.030 |
Why?
|
| Communication | 1 | 2018 | 329 | 0.030 |
Why?
|
| Translations | 1 | 2015 | 12 | 0.030 |
Why?
|
| Culture | 1 | 2015 | 75 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2014 | 55 | 0.030 |
Why?
|
| Mice | 1 | 2006 | 8474 | 0.030 |
Why?
|
| Chromosomes, Insect | 1 | 2014 | 1 | 0.030 |
Why?
|
| Titanium | 1 | 2015 | 118 | 0.030 |
Why?
|
| Centromere | 1 | 2014 | 15 | 0.030 |
Why?
|
| Laboratories | 1 | 2014 | 44 | 0.030 |
Why?
|
| London | 1 | 2013 | 12 | 0.030 |
Why?
|
| Italy | 1 | 2013 | 36 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2014 | 172 | 0.030 |
Why?
|
| Isoleucine | 1 | 2013 | 7 | 0.030 |
Why?
|
| Consensus | 1 | 2014 | 211 | 0.030 |
Why?
|
| Deglutition | 1 | 2016 | 221 | 0.030 |
Why?
|
| Leucine | 1 | 2013 | 41 | 0.030 |
Why?
|
| Breeding | 1 | 2013 | 15 | 0.030 |
Why?
|
| Population Growth | 1 | 2013 | 6 | 0.030 |
Why?
|
| Hereditary Sensory and Motor Neuropathy | 1 | 2012 | 2 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 235 | 0.030 |
Why?
|
| Electromyography | 1 | 2013 | 184 | 0.030 |
Why?
|
| Physical Examination | 1 | 2013 | 152 | 0.030 |
Why?
|
| Pedigree | 1 | 2012 | 159 | 0.030 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2012 | 6 | 0.030 |
Why?
|
| Naloxone | 1 | 2012 | 56 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 284 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2012 | 219 | 0.030 |
Why?
|
| Self Concept | 1 | 2012 | 132 | 0.030 |
Why?
|
| Sensation | 1 | 2012 | 49 | 0.030 |
Why?
|
| Ankle | 1 | 2012 | 45 | 0.020 |
Why?
|
| Memory, Short-Term | 1 | 2012 | 79 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2011 | 219 | 0.020 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2011 | 2 | 0.020 |
Why?
|
| Biopsy | 1 | 2013 | 540 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2013 | 714 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 792 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2012 | 328 | 0.020 |
Why?
|
| Sex | 1 | 2010 | 7 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 2012 | 184 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2013 | 383 | 0.020 |
Why?
|
| Employment | 1 | 2011 | 154 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2013 | 622 | 0.020 |
Why?
|
| Receptors, Cholinergic | 1 | 2010 | 30 | 0.020 |
Why?
|
| NAV1.4 Voltage-Gated Sodium Channel | 1 | 2010 | 1 | 0.020 |
Why?
|
| Ryanodine | 1 | 2010 | 7 | 0.020 |
Why?
|
| Sodium Channels | 1 | 2010 | 24 | 0.020 |
Why?
|
| Electron Transport Complex IV | 1 | 2010 | 33 | 0.020 |
Why?
|
| Tritium | 1 | 2010 | 101 | 0.020 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2010 | 28 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2010 | 100 | 0.020 |
Why?
|
| Calcium Channels, L-Type | 1 | 2010 | 34 | 0.020 |
Why?
|
| Rituximab | 1 | 2010 | 61 | 0.020 |
Why?
|
| Calcium Channels | 1 | 2010 | 59 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2010 | 100 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 159 | 0.020 |
Why?
|
| Lysine | 1 | 2010 | 96 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2010 | 200 | 0.020 |
Why?
|
| Caffeine | 1 | 2010 | 81 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2014 | 718 | 0.020 |
Why?
|
| Family Health | 1 | 2010 | 83 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2010 | 204 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2010 | 195 | 0.020 |
Why?
|
| Arginine | 1 | 2010 | 102 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 1465 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 948 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2009 | 91 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2008 | 40 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 782 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2008 | 144 | 0.020 |
Why?
|
| Glipizide | 1 | 2007 | 7 | 0.020 |
Why?
|
| Biomarkers | 1 | 2013 | 1593 | 0.020 |
Why?
|
| Pain | 1 | 2011 | 472 | 0.020 |
Why?
|
| Basal Metabolism | 1 | 2007 | 22 | 0.020 |
Why?
|
| Conservation of Natural Resources | 1 | 2007 | 19 | 0.020 |
Why?
|
| Metformin | 1 | 2007 | 63 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2007 | 165 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 1426 | 0.020 |
Why?
|
| Calcium | 1 | 2010 | 929 | 0.020 |
Why?
|
| Antioxidants | 1 | 2007 | 304 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 1083 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 1447 | 0.020 |
Why?
|
| Insulin | 1 | 2007 | 619 | 0.010 |
Why?
|
| Dehydration | 1 | 2004 | 15 | 0.010 |
Why?
|
| Body Water | 1 | 2004 | 35 | 0.010 |
Why?
|
| Education | 1 | 2004 | 83 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 2004 | 78 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 2223 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2007 | 2689 | 0.010 |
Why?
|